OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700 leading-edge peer reviewed Open Access Journals and organizes over 1000 International Conferences annually all over the world. OMICS International journals have over 10 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 50,000 eminent personalities that ensure a rapid, quality and quick review process. OMICS International signed an agreement with more than 1000 International Societies to make healthcare information Open Access.
OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way. OMICS Journals are poised in excellence by publishing high quality research. OMICS International follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website: http://omicsonline.org/Submitmanuscript.php
Min Li
Editor-in-Chief
Associate Professor
Director of Cancer Research Program
University of Texas
USA
Dr. Min Li got his PhD from Emory University at Atlanta, Georgia in 2002. Under the supervision of Dr. Richard W. Compan, a world renowned virologist and immunologist, Dr. Li studied the regulation of a retrovirus envelope protein induced membrane fusion and the association with lipid rafts. He then moved on to Baylor College of Medicine at Houston, Texas, and started his career in cancer research as an Assistant Professor in 2004. Dr. Li joined the University of Texas Health Science Center at Houston, Medical School in 2010 as the Director of Cancer Research Program. His research interests include pancreatic cancer and brain tumor pathogenesis, translational research, new therapies and tumor vaccine development. Dr. Lis group is the first one to identify a zinc transporter (ZIP4) as a new molecular target in pancreatic cancer, and has developed a novel therapy to treat this malignancy.
My current research projects focus on pancreatic cancer and brain tumor pathogenesis, translational research, new therapies (shRNA therapy, small molecule therapy, and nutrition/diet therapy), and tumor vaccine development. Due to the difficulty in diagnosing pancreatic adenocarcinoma and glioma, and its high resistance to conventional chemotherapy and radiotherapy, new diagnostic and therapeutic strategies are urgently needed for these malignant disease.
For Upcoming Conferences

- http://www.conferenceseries.com/
OMICS International Open Access Membership enables academic and research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors. For more details and benefits, click on the link below: http://omicsonline.org/membership.php